Safety and immunogenicity of mRNA COVID‐19 vaccine in inpatients with muscular dystrophy

INTRODUCTION/AIMS: Due to muscular weakness and cardiopulmonary dysfunction, patients with muscular dystrophy (MD) have an increased risk of serious complications from coronavirus disease‐2019 (COVID‐19). Although vaccination is recommended, COVID‐19 vaccination safety and immunogenicity in these pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Tomoko, Saito, Toshio, Hashimoto, Hiroya, Ogata, Katsuhisa, Kobayashi, Michio, Takada, Hiroto, Kuru, Satoshi, Kimura, Takashi, Nakamura, Akinori, Matsumura, Tsuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878062/
https://www.ncbi.nlm.nih.gov/pubmed/36478587
http://dx.doi.org/10.1002/mus.27761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878062/
https://www.ncbi.nlm.nih.gov/pubmed/36478587
http://dx.doi.org/10.1002/mus.27761

Ejemplares similares